Patient baseline characteristics
| Characteristics | N=57 |
| Age (years), median (Q1–Q3) | 56.5 (45.8–63.8) |
| Sex, n (%) | |
| Male | 30 (52.6) |
| Female | 27 (47.4) |
| ECOG PS, n (%) | |
| 0 | 20 (35.1) |
| 1 | 37 (64.9) |
| Primary tumor location, n (%) | |
| Right-sided | 31 (54.4) |
| Left-sided | 25 (43.9) |
| Right and left location | 1 (1.8) |
| Mutation status, n (%) | |
| RAS/RAF wild type | 19 (33.3) |
| RAS mutation | 28 (49.1) |
| BRAF mutation | 10 (17.5) |
| Origin of MMR deficiency, n (%) | |
| Lynch-related | 32 (56.1) |
| Known germline mutation | 19 (59.4) |
| Sporadic | 16 (28.1) |
| Unknown | 9 (15.8) |
| Number of metastatic sites, n (%) | |
| 1 | 16 (28.1) |
| 2 | 25 (43.9) |
| >2 | 16 (28.1) |
| Number of prior lines, n (%) | |
| 1 | 5 (8.8) |
| 2 | 24 (42.1) |
| >2 | 27 (47.4) |
| Missing | 1 (1.8) |
| Prior treatments, n (%) | |
| 5-FU/capecitabine | 57 (100.0) |
| Oxaliplatin | 57 (100.0) |
| Irinotecan | 55 (96.5) |
| Trifluridine/tipiracil | 4 (7.0) |
| Regorafenib | 5 (8.8) |
| Bevacizumab/aflibercept | 33 (57.9) |
| Cetuximab/panitumumab | 26 (45.6) |
ECOG PS, The Eastern Cooperative Oncology Group Performance Status; 5-FU, 5-fluorouracil; MMR, DNA mismatch repair.